OR WAIT null SECS
April 25, 2025
Article
In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.
April 24, 2025
These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.
April 23, 2025
In new preference research, the average participant with AA was willing to trade approximately 5 years of life to avoid impacts associated with 50–100% scalp hair loss.
Healthier hair and scalp according to Hair & Scalp CARE questionnaire responses was linked to lower levels of perceived stress and good sleep health.
The findings may facilitate accurate diagnoses, which could help patients slow or stop permanent hair loss.
April 19, 2025
Our top 5 headlines spotlight FDA approvals for maralixibat and dupilumab, plus key trial results in diabetes, cardiovascular disease, and retinal vein occlusion.
April 15, 2025
This network meta-analysis compares the relative effectiveness and safety of different monotherapies for patients living with alopecia areata.
Side effects of baricitinib were well within safety parameters, indicating the drug’s viability as a alopecia treatment for adults.
This systematic review highlights current research on ruxolitinib’s off-label use in dermatology, specifically for conditions such as alopecia and psoriasis.
April 14, 2025
These data on 5α-reductase inhibitors highlight impacts on patients with benign prostatic hyperplasia or androgenic alopecia.
